These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 25894871)
1. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment? Aoki Y; Douglas AG; Wood MJ Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871 [No Abstract] [Full Text] [Related]
2. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Mizielinska S; Isaacs AM Curr Opin Neurol; 2014 Oct; 27(5):515-23. PubMed ID: 25188012 [TBL] [Abstract][Full Text] [Related]
3. Amyotrophic lateral sclerosis and gene therapy. Miller TM; Smith RA; Cleveland DW Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606 [No Abstract] [Full Text] [Related]
4. Tofersen: First Approval. Blair HA Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681 [TBL] [Abstract][Full Text] [Related]
5. Effect of Mutations in SOD1 and C9orf72 Genes on Autophagy in Lymphomonocytes in Myotrophic Lateral Sclerosis. Kochergin IA; Shpilyukova YA; Lysogorskaia EV; Abramycheva NY; Zakharova MN; Illarioshkin SN Bull Exp Biol Med; 2019 Sep; 167(5):667-670. PubMed ID: 31625064 [TBL] [Abstract][Full Text] [Related]
6. Experimental therapies hold promise for treating amyotrophic lateral sclerosis. Friedrich MJ JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517 [No Abstract] [Full Text] [Related]
7. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future]. Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756 [TBL] [Abstract][Full Text] [Related]
8. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Chiò A; Borghero G; Restagno G; Mora G; Drepper C; Traynor BJ; Sendtner M; Brunetti M; Ossola I; Calvo A; Pugliatti M; Sotgiu MA; Murru MR; Marrosu MG; Marrosu F; Marinou K; Mandrioli J; Sola P; Caponnetto C; Mancardi G; Mandich P; La Bella V; Spataro R; Conte A; Monsurrò MR; Tedeschi G; Pisano F; Bartolomei I; Salvi F; Lauria Pinter G; Simone I; Logroscino G; Gambardella A; Quattrone A; Lunetta C; Volanti P; Zollino M; Penco S; Battistini S; ; Renton AE; Majounie E; Abramzon Y; Conforti FL; Giannini F; Corbo M; Sabatelli M Brain; 2012 Mar; 135(Pt 3):784-93. PubMed ID: 22366794 [TBL] [Abstract][Full Text] [Related]
10. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1 Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164 [TBL] [Abstract][Full Text] [Related]